{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T01:12:59Z","timestamp":1768093979394,"version":"3.49.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T00:00:00Z","timestamp":1516838400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s12016-018-8674-3","type":"journal-article","created":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T09:09:13Z","timestamp":1516871353000},"page":"205-216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Biological Therapies for Eosinophilic Esophagitis: Where Do We Stand?"],"prefix":"10.1007","volume":"55","author":[{"given":"Emily","family":"Ko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7177-2791","authenticated-orcid":false,"given":"Mirna","family":"Chehade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,25]]},"reference":[{"issue":"1","key":"8674_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jaci.2011.02.040","volume":"128","author":"CA Liacouras","year":"2011","unstructured":"Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, Burks AW, Chehade M, Collins MH, Dellon ES, Dohil R, Falk GW, Gonsalves N, Gupta SK, Katzka DA, Lucendo AJ, Markowitz JE, Noel RJ, Odze RD, Putnam PE, Richter JE, Romero Y, Ruchelli E, Sampson HA, Schoepfer A, Shaheen NJ, Sicherer SH, Spechler S, Spergel JM, Straumann A, Wershil BK, Rothenberg ME, Aceves SS (2011) Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 128(1):3\u201320 e26; quiz 21-22. \n                    https:\/\/doi.org\/10.1016\/j.jaci.2011.02.040","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"8674_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cgh.2015.08.034","volume":"14","author":"FJ Moawad","year":"2016","unstructured":"Moawad FJ, Dellon ES, Achem SR, Ljuldjuraj T, Green DJ, Maydonovitch CL, Brizuela DR, Gupta SK, Chehade M (2016) Effects of race and sex on features of eosinophilic esophagitis. Clin Gastroenterol Hepatol 14(1):23\u201330. \n                    https:\/\/doi.org\/10.1016\/j.cgh.2015.08.034","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"8674_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.iac.2011.11.006","volume":"32","author":"JA Lieberman","year":"2012","unstructured":"Lieberman JA, Chehade M (2012) Eosinophilic esophagitis: diagnosis and management. Immunol Allergy Clin N Am 32(1):67\u201381. \n                    https:\/\/doi.org\/10.1016\/j.iac.2011.11.006","journal-title":"Immunol Allergy Clin N Am"},{"issue":"2","key":"8674_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.gtc.2014.02.012","volume":"43","author":"CA Liacouras","year":"2014","unstructured":"Liacouras CA, Spergel J, Gober LM (2014) Eosinophilic esophagitis: clinical presentation in children. Gastroenterol Clin N Am 43(2):219\u2013229. \n                    https:\/\/doi.org\/10.1016\/j.gtc.2014.02.012","journal-title":"Gastroenterol Clin N Am"},{"issue":"11","key":"8674_CR5","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/j.cgh.2017.05.048","volume":"15","author":"AF Kagalwalla","year":"2017","unstructured":"Kagalwalla AF, Wechsler JB, Amsden K, Schwartz S, Makhija M, Olive A, Davis CM, Manuel-Rubio M, Marcus S, Shaykin R, Sulkowski M, Johnson K, Ross JN, Riffle ME, Groetch M, Melin-Aldana H, Schady D, Palac H, Kim KYA, Wershil BK, Collins MH, Chehade M (2017) Efficacy of a 4-food elimination diet for children with eosinophilic esophagitis. Clin Gastroenterol Hepatol 15(11):1698\u20131707 e1697. \n                    https:\/\/doi.org\/10.1016\/j.cgh.2017.05.048","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"8674_CR6","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1053\/j.gastro.2014.05.036","volume":"147","author":"F Clayton","year":"2014","unstructured":"Clayton F, Fang JC, Gleich GJ, Lucendo AJ, Olalla JM, Vinson LA, Lowichik A, Chen X, Emerson L, Cox K, O\u2019Gorman MA, Peterson KA (2014) Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE. Gastroenterology 147(3):602\u2013609. \n                    https:\/\/doi.org\/10.1053\/j.gastro.2014.05.036","journal-title":"Gastroenterology"},{"issue":"4","key":"8674_CR7","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1572-0241.2003.07390.x","volume":"98","author":"JE Markowitz","year":"2003","unstructured":"Markowitz JE, Spergel JM, Ruchelli E, Liacouras CA (2003) Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents. Am J Gastroenterol 98(4):777\u2013782. \n                    https:\/\/doi.org\/10.1111\/j.1572-0241.2003.07390.x","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"8674_CR8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jaip.2016.12.026","volume":"5","author":"M Groetch","year":"2017","unstructured":"Groetch M, Venter C, Skypala I, Vlieg-Boerstra B, Grimshaw K, Durban R, Cassin A, Henry M, Kliewer K, Kabbash L, Atkins D, Nowak-W\u0119grzyn A, Holbreich M, Chehade M, Eosinophilic Gastrointestinal Disorders Committee of the American Academy of Allergy, Asthma and Immunology (2017) Dietary therapy and nutrition Management of Eosinophilic Esophagitis: a work group report of the American Academy of allergy, asthma, and immunology. J Allergy Clin Immunol Pract 5(2):312\u2013324 e329. \n                    https:\/\/doi.org\/10.1016\/j.jaip.2016.12.026","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"8674_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jaci.2012.05.021","volume":"130","author":"JM Spergel","year":"2012","unstructured":"Spergel JM, Brown-Whitehorn TF, Cianferoni A, Shuker M, Wang ML, Verma R, Liacouras CA (2012) Identification of causative foods in children with eosinophilic esophagitis treated with an elimination diet. J Allergy Clin Immunol 130(2):461\u2013467 e465. \n                    https:\/\/doi.org\/10.1016\/j.jaci.2012.05.021","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"8674_CR10","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1053\/j.gastro.2014.02.006","volume":"146","author":"A Arias","year":"2014","unstructured":"Arias A, Gonzalez-Cervera J, Tenias JM, Lucendo AJ (2014) Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. Gastroenterology 146(7):1639\u20131648. \n                    https:\/\/doi.org\/10.1053\/j.gastro.2014.02.006","journal-title":"Gastroenterology"},{"issue":"9","key":"8674_CR11","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.cgh.2006.05.026","volume":"4","author":"AF Kagalwalla","year":"2006","unstructured":"Kagalwalla AF, Sentongo TA, Ritz S, Hess T, Nelson SP, Emerick KM, Melin\u2013Aldana H, Li BUK (2006) Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin Gastroenterol Hepatol 4(9):1097\u20131102. \n                    https:\/\/doi.org\/10.1016\/j.cgh.2006.05.026","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"8674_CR12","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jaci.2012.12.664","volume":"131","author":"AJ Lucendo","year":"2013","unstructured":"Lucendo AJ, Arias A, Gonzalez-Cervera J et al (2013) Empiric 6-food elimination diet induced and maintained prolonged remission in patients with adult eosinophilic esophagitis: a prospective study on the food cause of the disease. J Allergy Clin Immunol 131(3):797\u2013804. \n                    https:\/\/doi.org\/10.1016\/j.jaci.2012.12.664","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"8674_CR13","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.jaci.2014.07.023","volume":"134","author":"J Molina-Infante","year":"2014","unstructured":"Molina-Infante J, Arias A, Barrio J, Rodriguez-Sanchez J, Sanchez-Cazalilla M, Lucendo AJ (2014) Four-food group elimination diet for adult eosinophilic esophagitis: a prospective multicenter study. J Allergy Clin Immunol 134(5):1093\u20131099 e1091. \n                    https:\/\/doi.org\/10.1016\/j.jaci.2014.07.023","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"8674_CR14","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.jaci.2017.08.038","volume":"141","author":"Javier Molina-Infante","year":"2018","unstructured":"Molina-Infante J, Arias A, Alcedo J, et al (2017) Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: the 2\u20134-6 Study. J Allergy Clin Immunol. \n                    https:\/\/doi.org\/10.1016\/j.jaci.2017.08.038","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"4","key":"8674_CR15","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/00005176-199804000-00004","volume":"26","author":"CA Liacouras","year":"1998","unstructured":"Liacouras CA, Wenner WJ, Brown K, Ruchelli E (1998) Primary eosinophilic esophagitis in children: successful treatment with oral corticosteroids. J Pediatr Gastroenterol Nutr 26(4):380\u2013385. \n                    https:\/\/doi.org\/10.1097\/00005176-199804000-00004","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"8674_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.revmed.2012.11.005","volume":"34","author":"K Briot","year":"2013","unstructured":"Briot K, Roux C (2013) Corticosteroid-induced osteoporosis. Rev Med Interne 34(5):315\u2013323. \n                    https:\/\/doi.org\/10.1016\/j.revmed.2012.11.005","journal-title":"Rev Med Interne"},{"issue":"6","key":"8674_CR17","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/jgh.13281","volume":"31","author":"AR Murali","year":"2016","unstructured":"Murali AR, Gupta A, Attar BM, Ravi V, Koduru P (2016) Topical steroids in eosinophilic esophagitis: systematic review and meta-analysis of placebo-controlled randomized clinical trials. J Gastroenterol Hepatol 31(6):1111\u20131119. \n                    https:\/\/doi.org\/10.1111\/jgh.13281","journal-title":"J Gastroenterol Hepatol"},{"issue":"8","key":"8674_CR18","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ajg.2016.238","volume":"111","author":"DA Andreae","year":"2016","unstructured":"Andreae DA, Hanna MG, Magid MS, Malerba S, Andreae MH, Bagiella E, Chehade M (2016) Swallowed fluticasone propionate is an effective long-term maintenance therapy for children with eosinophilic esophagitis. Am J Gastroenterol 111(8):1187\u20131197. \n                    https:\/\/doi.org\/10.1038\/ajg.2016.238","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"8674_CR19","doi-asserted-by":"publisher","first-page":"495-503.e8","DOI":"10.1016\/j.cgh.2017.06.036","volume":"16","author":"Vincent Mukkada","year":"2018","unstructured":"Mukkada V, Falk GW, Eichinger CS, King D, Todorova L, Shaheen NJ (2017) Health-Related Quality of Life and Costs Associated With Eosinophilic Esophagitis: A Systematic Review. Clin Gastroenterol Hepatol. \n                    https:\/\/doi.org\/10.1016\/j.cgh.2017.06.036","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"1","key":"8674_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.giec.2007.09.013","volume":"18","author":"M Chehade","year":"2008","unstructured":"Chehade M (2008) Translational research on the pathogenesis of eosinophilic esophagitis. Gastrointest Endosc Clin N Am 18(1):145\u2013156; x. \n                    https:\/\/doi.org\/10.1016\/j.giec.2007.09.013","journal-title":"Gastrointest Endosc Clin N Am"},{"issue":"6","key":"8674_CR21","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1067\/mai.2001.119917","volume":"108","author":"A Straumann","year":"2001","unstructured":"Straumann A, Bauer M, Fischer B, Blaser K, Simon HU (2001) Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol 108(6):954\u2013961. \n                    https:\/\/doi.org\/10.1067\/mai.2001.119917","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"8674_CR22","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.jaci.2007.10.024","volume":"120","author":"C Blanchard","year":"2007","unstructured":"Blanchard C, Mingler MK, Vicario M, Abonia JP, Wu YY, Lu TX, Collins MH, Putnam PE, Wells SI, Rothenberg ME (2007) IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. J Allergy Clin Immunol 120(6):1292\u20131300. \n                    https:\/\/doi.org\/10.1016\/j.jaci.2007.10.024","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"8674_CR23","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.4049\/jimmunol.168.5.2464","volume":"168","author":"A Mishra","year":"2002","unstructured":"Mishra A, Hogan SP, Brandt EB, Rothenberg ME (2002) IL-5 promotes eosinophil trafficking to the esophagus. J Immunol 168(5):2464\u20132469. \n                    https:\/\/doi.org\/10.4049\/jimmunol.168.5.2464","journal-title":"J Immunol"},{"issue":"2","key":"8674_CR24","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1172\/JCI26679","volume":"116","author":"C Blanchard","year":"2006","unstructured":"Blanchard C, Wang N, Stringer KF, Mishra A, Fulkerson PC, Abonia JP, Jameson SC, Kirby C, Konikoff MR, Collins MH, Cohen MB, Akers R, Hogan SP, Assa'ad AH, Putnam PE, Aronow BJ, Rothenberg ME (2006) Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest 116(2):536\u2013547. \n                    https:\/\/doi.org\/10.1172\/JCI26679","journal-title":"J Clin Invest"},{"issue":"6","key":"8674_CR25","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.jaci.2006.09.007","volume":"118","author":"ML Stein","year":"2006","unstructured":"Stein ML, Collins MH, Villanueva JM et al (2006) Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 118(6):1312\u20131319. \n                    https:\/\/doi.org\/10.1016\/j.jaci.2006.09.007","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"8674_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/gut.2009.178558","volume":"59","author":"A Straumann","year":"2010","unstructured":"Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, Beglinger C, Smith DA, Patel J, Byrne M, Simon HU (2010) Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 59(1):21\u201330. \n                    https:\/\/doi.org\/10.1136\/gut.2009.178558","journal-title":"Gut"},{"issue":"5","key":"8674_CR27","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1053\/j.gastro.2011.07.044","volume":"141","author":"AH Assa'ad","year":"2011","unstructured":"Assa'ad AH, Gupta SK, Collins MH, Thomson M, Heath AT, Smith DA, Perschy TL, Jurgensen CH, Ortega HG, Aceves SS (2011) An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 141(5):1593\u20131604. \n                    https:\/\/doi.org\/10.1053\/j.gastro.2011.07.044","journal-title":"Gastroenterology"},{"issue":"2","key":"8674_CR28","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jaci.2011.11.044","volume":"129","author":"JM Spergel","year":"2012","unstructured":"Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs G III, O\u2019Gorman MA, Abonia JP, Young J, Henkel T, Wilkins HJ, Liacouras CA (2012) Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 129(2):456\u2013463, 463 e451-453. \n                    https:\/\/doi.org\/10.1016\/j.jaci.2011.11.044","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"8674_CR29","doi-asserted-by":"publisher","first-page":"e0113483","DOI":"10.1371\/journal.pone.0113483","volume":"10","author":"D Loizou","year":"2015","unstructured":"Loizou D, Enav B, Komlodi-Pasztor E, Hider P, Kim-Chang J, Noonan L, Taber T, Kaushal S, Limgala R, Brown M, Gupta R, Balba N, Goker-Alpan O, Khojah A, Alpan O (2015) A pilot study of omalizumab in eosinophilic esophagitis. PLoS One 10(3):e0113483. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0113483","journal-title":"PLoS One"},{"issue":"2","key":"8674_CR30","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jaci.2008.06.012","volume":"122","author":"A Straumann","year":"2008","unstructured":"Straumann A, Bussmann C, Conus S, Beglinger C, Simon HU (2008) Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis. J Allergy Clin Immunol 122(2):425\u2013427. \n                    https:\/\/doi.org\/10.1016\/j.jaci.2008.06.012","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"8674_CR31","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jaci.2014.07.049","volume":"135","author":"ME Rothenberg","year":"2015","unstructured":"Rothenberg ME, Wen T, Greenberg A, Alpan O, Enav B, Hirano I, Nadeau K, Kaiser S, Peters T, Perez A, Jones I, Arm JP, Strieter RM, Sabo R, Gunawardena KA (2015) Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol 135(2):500\u2013507. \n                    https:\/\/doi.org\/10.1016\/j.jaci.2014.07.049","journal-title":"J Allergy Clin Immunol"},{"issue":"22","key":"8674_CR32","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1056\/NEJM199805283382206","volume":"338","author":"ME Rothenberg","year":"1998","unstructured":"Rothenberg ME (1998) Eosinophilia. N Engl J Med 338(22):1592\u20131600. \n                    https:\/\/doi.org\/10.1056\/NEJM199805283382206","journal-title":"N Engl J Med"},{"issue":"4","key":"8674_CR33","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1084\/jem.182.4.1169","volume":"182","author":"PD Collins","year":"1995","unstructured":"Collins PD, Marleau S, Griffiths-Johnson DA, Jose PJ, Williams TJ (1995) Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med 182(4):1169\u20131174. \n                    https:\/\/doi.org\/10.1084\/jem.182.4.1169","journal-title":"J Exp Med"},{"issue":"1","key":"8674_CR34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/01.mpg.0000188740.38757.d2","volume":"42","author":"SK Gupta","year":"2006","unstructured":"Gupta SK, Fitzgerald JF, Kondratyuk T, HogenEsch H (2006) Cytokine expression in normal and inflamed esophageal mucosa: a study into the pathogenesis of allergic eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 42(1):22\u201326. \n                    https:\/\/doi.org\/10.1097\/01.mpg.0000188740.38757.d2","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"10","key":"8674_CR35","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1056\/NEJMoa0805435","volume":"360","author":"P Nair","year":"2009","unstructured":"Nair P, Pizzichini MM, Kjarsgaard M et al (2009) Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 360(10):985\u2013993. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0805435","journal-title":"N Engl J Med"},{"issue":"13","key":"8674_CR36","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P, MENSA Investigators (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371(13):1198\u20131207. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1403290","journal-title":"N Engl J Med"},{"issue":"12","key":"8674_CR37","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa070812","volume":"358","author":"ME Rothenberg","year":"2008","unstructured":"Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ, Mepolizumab HES Study Group (2008) Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 358(12):1215\u20131228. \n                    https:\/\/doi.org\/10.1056\/NEJMoa070812","journal-title":"N Engl J Med"},{"issue":"3","key":"8674_CR38","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jama.2017.8372","volume":"318","author":"JL McCracken","year":"2017","unstructured":"McCracken JL, Veeranki SP, Ameredes BT, Calhoun WJ (2017) Diagnosis and Management of Asthma in adults: a review. JAMA 318(3):279\u2013290. \n                    https:\/\/doi.org\/10.1001\/jama.2017.8372","journal-title":"JAMA"},{"issue":"5","key":"8674_CR39","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S1010-7940(00)00542-X","volume":"18","author":"GM Lindsay","year":"2000","unstructured":"Lindsay GM, Hanlon P, Smith LN, Wheatley DJ (2000) Assessment of changes in general health status using the short-form 36 questionnaire 1 year following coronary artery bypass grafting. Eur J Cardiothorac Surg 18(5):557\u2013564. \n                    https:\/\/doi.org\/10.1016\/S1010-7940(00)00542-X","journal-title":"Eur J Cardiothorac Surg"},{"issue":"1","key":"8674_CR40","first-page":"97","volume":"26","author":"J Thumboo","year":"1999","unstructured":"Thumboo J, Fong KY, Ng TP, Leong KH, Feng PH, Thio ST, Boey ML (1999) Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. J Rheumatol 26(1):97\u2013102","journal-title":"J Rheumatol"},{"issue":"6","key":"8674_CR41","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1053\/j.gastro.2003.09.024","volume":"125","author":"A Straumann","year":"2003","unstructured":"Straumann A, Spichtin HP, Grize L, Bucher KA, Beglinger C, Simon HU (2003) Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 125(6):1660\u20131669. \n                    https:\/\/doi.org\/10.1053\/j.gastro.2003.09.024","journal-title":"Gastroenterology"},{"issue":"12","key":"8674_CR42","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1185\/03007990802536900","volume":"24","author":"EM Flood","year":"2008","unstructured":"Flood EM, Beusterien KM, Amonkar MM, Jurgensen CH, Dewit OE, Kahl LP, Matza LS (2008) Patient and caregiver perspective on pediatric eosinophilic esophagitis and newly developed symptom questionnaires. Curr Med Res Opin 24(12):3369\u20133381. \n                    https:\/\/doi.org\/10.1185\/03007990802536900","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"8674_CR43","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O'Brien C, Korn S (2015) Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 3(5):355\u2013366. \n                    https:\/\/doi.org\/10.1016\/S2213-2600(15)00042-9","journal-title":"Lancet Respir Med"},{"issue":"4","key":"8674_CR44","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2213-2600(15)00119-8","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro M, Zangrilli J, Wechsler ME (2015) Corrections. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 3(4):e15. \n                    https:\/\/doi.org\/10.1016\/S2213-2600(15)00119-8","journal-title":"Lancet Respir Med"},{"issue":"5","key":"8674_CR45","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1053\/j.gastro.2006.08.033","volume":"131","author":"MR Konikoff","year":"2006","unstructured":"Konikoff MR, Noel RJ, Blanchard C, Kirby C, Jameson SC, Buckmeier BK, Akers R, Cohen MB, Collins MH, Assa\u2019ad AH, Aceves SS, Putnam PE, Rothenberg ME (2006) A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 131(5):1381\u20131391. \n                    https:\/\/doi.org\/10.1053\/j.gastro.2006.08.033","journal-title":"Gastroenterology"},{"issue":"6","key":"8674_CR46","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.anai.2010.03.018","volume":"104","author":"EA Erwin","year":"2010","unstructured":"Erwin EA, James HR, Gutekunst HM, Russo JM, Kelleher KJ, Platts-Mills TA (2010) Serum IgE measurement and detection of food allergy in pediatric patients with eosinophilic esophagitis. Ann Allergy Asthma Immunol 104(6):496\u2013502. \n                    https:\/\/doi.org\/10.1016\/j.anai.2010.03.018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"8674_CR47","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/j.1365-2559.2012.4303.x","volume":"61","author":"DJ Mulder","year":"2012","unstructured":"Mulder DJ, Mak N, Hurlbut DJ, Justinich CJ (2012) Atopic and non-atopic eosinophilic oesophagitis are distinguished by immunoglobulin E-bearing intraepithelial mast cells. Histopathology 61(5):810\u2013822. \n                    https:\/\/doi.org\/10.1111\/j.1365-2559.2012.4303.x","journal-title":"Histopathology"},{"issue":"1","key":"8674_CR48","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/gut.2009.178020","volume":"59","author":"M Vicario","year":"2010","unstructured":"Vicario M, Blanchard C, Stringer KF, Collins MH, Mingler MK, Ahrens A, Putnam PE, Abonia JP, Santos J, Rothenberg ME (2010) Local B cells and IgE production in the oesophageal mucosa in eosinophilic oesophagitis. Gut 59(1):12\u201320. \n                    https:\/\/doi.org\/10.1136\/gut.2009.178020","journal-title":"Gut"},{"issue":"5","key":"8674_CR49","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.jaci.2017.03.002","volume":"139","author":"BE Chipps","year":"2017","unstructured":"Chipps BE, Lanier B, Milgrom H, Deschildre A, Hedlin G, Szefler SJ, Kattan M, Kianifard F, Ortiz B, Haselkorn T, Iqbal A, Ros\u00e9n K, Trzaskoma B, Busse WW (2017) Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. J Allergy Clin Immunol 139(5):1431\u20131444. \n                    https:\/\/doi.org\/10.1016\/j.jaci.2017.03.002","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"8674_CR50","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s00431-011-1540-4","volume":"170","author":"R Rocha","year":"2011","unstructured":"Rocha R, Vitor AB, Trindade E, Lima R, Tavares M, Lopes J, Dias JA (2011) Omalizumab in the treatment of eosinophilic esophagitis and food allergy. Eur J Pediatr 170(11):1471\u20131474. \n                    https:\/\/doi.org\/10.1007\/s00431-011-1540-4","journal-title":"Eur J Pediatr"},{"issue":"3","key":"8674_CR51","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1365-2249.2005.02875.x","volume":"141","author":"S Kagami","year":"2005","unstructured":"Kagami S, Saeki H, Komine M, Kakinuma T, Tsunemi Y, Nakamura K, Sasaki K, Asahina A, Tamaki K (2005) Interleukin-4 and interleukin-13 enhance CCL26 production in a human keratinocyte cell line, HaCaT cells. Clin Exp Immunol 141(3):459\u2013466. \n                    https:\/\/doi.org\/10.1111\/j.1365-2249.2005.02875.x","journal-title":"Clin Exp Immunol"},{"issue":"15","key":"8674_CR52","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ et al (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. N Engl J Med 337(15):1029\u20131035. \n                    https:\/\/doi.org\/10.1056\/NEJM199710093371502","journal-title":"N Engl J Med"},{"issue":"8930","key":"8674_CR53","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","volume":"344","author":"MJ Elliott","year":"1994","unstructured":"Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl JA, Woody JN (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344(8930):1105\u20131110. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(94)90628-9","journal-title":"Lancet"},{"issue":"5","key":"8674_CR54","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.gastro.2003.07.007","volume":"125","author":"A Mishra","year":"2003","unstructured":"Mishra A, Rothenberg ME (2003) Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism. Gastroenterology 125(5):1419\u20131427. \n                    https:\/\/doi.org\/10.1016\/j.gastro.2003.07.007","journal-title":"Gastroenterology"},{"issue":"6","key":"8674_CR55","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.jaci.2015.03.004","volume":"135","author":"LJ Martin","year":"2015","unstructured":"Martin LJ, Franciosi JP, Collins MH, Abonia JP, Lee JJ, Hommel KA, Varni JW, Grotjan JT, Eby M, He H, Marsolo K, Putnam PE, Garza JM, Kaul A, Wen T, Rothenberg ME (2015) Pediatric eosinophilic esophagitis symptom scores (PEESS v2.0) identify histologic and molecular correlates of the key clinical features of disease. J Allergy Clin Immunol 135(6):1519\u20131528 e1518. \n                    https:\/\/doi.org\/10.1016\/j.jaci.2015.03.004","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"8674_CR56","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1053\/j.gastro.2014.08.028","volume":"147","author":"AM Schoepfer","year":"2014","unstructured":"Schoepfer AM, Straumann A, Panczak R, Coslovsky M, Kuehni CE, Maurer E, Haas NA, Romero Y, Hirano I, Alexander JA, Gonsalves N, Furuta GT, Dellon ES, Leung J, Collins MH, Bussmann C, Netzer P, Gupta SK, Aceves SS, Chehade M, Moawad FJ, Enders FT, Yost KJ, Taft TH, Kern E, Zwahlen M, Safroneeva E, International Eosinophilic Esophagitis Activity Index Study Group (2014) Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis. Gastroenterology 147(6):1255\u20131266 e1221. \n                    https:\/\/doi.org\/10.1053\/j.gastro.2014.08.028","journal-title":"Gastroenterology"},{"issue":"10056","key":"8674_CR57","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkstr\u00f6m V, Goldman M (2016) Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 388(10056):2115\u20132127. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(16)31324-1","journal-title":"Lancet"},{"issue":"10056","key":"8674_CR58","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkstr\u00f6m V, Aurivillius M, Goldman M (2016) Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 388(10056):2128\u20132141. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(16)31322-8","journal-title":"Lancet"},{"issue":"3","key":"8674_CR59","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1124\/jpet.109.153973","volume":"330","author":"D Soler","year":"2009","unstructured":"Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER (2009) The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 330(3):864\u2013875. \n                    https:\/\/doi.org\/10.1124\/jpet.109.153973","journal-title":"J Pharmacol Exp Ther"},{"issue":"24","key":"8674_CR60","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M, SOLO 1 and SOLO 2 Investigators (2016) Two phase 3 trials of Dupilumab versus placebo in atopic dermatitis. N Engl J Med 375(24):2335\u20132348. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1610020","journal-title":"N Engl J Med"},{"issue":"10086","key":"8674_CR61","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HCH, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kem\u00e9ny L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B (2017) Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389(10086):2287\u20132303. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(17)31191-1","journal-title":"Lancet"},{"issue":"7","key":"8674_CR62","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/ni805","volume":"3","author":"V Soumelis","year":"2002","unstructured":"Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, Gilliet M, Ho S, Antonenko S, Lauerma A, Smith K, Gorman D, Zurawski S, Abrams J, Menon S, McClanahan T, Waal-Malefyt R, Bazan F, Kastelein RA, Liu YJ (2002) Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 3(7):673\u2013680. \n                    https:\/\/doi.org\/10.1038\/ni805","journal-title":"Nat Immunol"},{"issue":"1","key":"8674_CR63","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jaci.2010.04.037","volume":"126","author":"JD Sherrill","year":"2010","unstructured":"Sherrill JD, Gao PS, Stucke EM, Blanchard C, Collins MH, Putnam PE, Franciosi JP, Kushner JP, Abonia JP, Assa'ad AH, Kovacic MB, Biagini Myers JM, Bochner BS, He H, Hershey GK, Martin LJ, Rothenberg ME (2010) Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis. J Allergy Clin Immunol 126(1):160\u2013165 e163. \n                    https:\/\/doi.org\/10.1016\/j.jaci.2010.04.037","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"8674_CR64","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1007\/s12325-017-0525-8","volume":"34","author":"CS Tripp","year":"2017","unstructured":"Tripp CS, Cuff C, Campbell AL, Hendrickson BA, Voss J, Melim T, Wu C, Cherniack AD, Kim K (2017) RPC4046, a novel anti-interleukin-13 antibody, blocks IL-13 binding to IL-13 alpha1 and alpha2 receptors: a randomized, double-blind, placebo-controlled, dose-escalation first-in-human study. Adv Ther 34(6):1364\u20131381. \n                    https:\/\/doi.org\/10.1007\/s12325-017-0525-8","journal-title":"Adv Ther"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-018-8674-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-018-8674-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-018-8674-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T03:37:15Z","timestamp":1548387435000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-018-8674-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,25]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["8674"],"URL":"https:\/\/doi.org\/10.1007\/s12016-018-8674-3","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,25]]},"assertion":[{"value":"25 January 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Emily Ko has nothing to disclose. Mirna Chehade has the following to disclose: received funding for research from Regeneron, Shire and Nutricia. Received consulting fees from Actelion, Shire and Allakos.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This articles does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human Participants and\/or Animals"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}